Hints and tips:
...On Monday, the French pharma group said it will pay $11.6bn in cash to acquire Bioverativ, which specialises in new treatments for the blood disorder....
...Sanofi paid a 63 per cent premium for haemophilia specialist Bioverativ....
...Robust dealmaking was already boosting the sector, he said, pointing to Celgene’s purchase of Juno Therapeutics and Sanofi’s purchase of Bioverativ....
...The Paris-based pharma company is paying $105 per share to acquire Bioverativ — a hefty 63 per cent premium based on the target company’s closing stock price on Friday....
...Sanofi said it would pay $11.6bn for the haemophilia specialist Bioverativ, a 63 per cent premium, while Celgene agreed to pay $9bn for Juno Therapeutics, a cellular therapy company — almost two times as...
...Meanwhile, Matthew Harrison at Morgan Stanley said the move “is not a downside call, but a timing call”, following a recent advance in the company’s shares after it spun off its hemophilia business, Bioverativ...
International Edition